Vaxart injects first subject in Phase 1 trial of its norovirus vaccine candidate in breastfeeding mothers

Trial to assess the ability of oral vaccine tablets to induce breast milk antibodies and transfer antibodies to young children

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced that it has enrolled the first subject in its Phase 1 clinical trial. The trial is evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate. About breastfeeding mothers.

“Initiating this study is an important step toward Vaxart’s goal of developing a vaccine that can reduce the significant global impact of norovirus in children under 5 years of age,” said Dr. James F. Cummings, Vaxart’s chief medical officer. Health Threat.” “We believe an oral norovirus vaccine pill may allow mothers to protect their babies from this highly contagious virus, for which there is currently no approved vaccine.”

Norovirus affects approximately 21 million people in the United States each year, and 15% of children under 5 years old are infected with norovirus each year. This means that about 3 million parents need to take time off from work (about 2.2 days on average) to care for their children.

Globally, norovirus has become the leading cause of pediatric gastroenteritis in health care settings in countries with rotavirus vaccine programs.¹ Childhood deaths from norovirus are rare in the United States but are more common in developing countries.

About VXA-NVV-108 clinical trials

This Phase 1, multicenter, randomized, double-blind, placebo-controlled single-dose, dose-ranging study was designed to evaluate the safety, tolerability and immunity of an oral bivalent GI.1/GII.4 norovirus vaccine in healthy lactating women. Original sex is 18 years old and above and nursing infants (30 days to 11 months). The study is expected to recruit approximately 76 subjects across seven sites in South Africa. Subjects will be randomly divided into high-dose or low-dose vaccine groups (N=30 in each group) or placebo group (N=16). The primary endpoints are:

The story continues

• Frequency, duration, and severity of required reactogenic symptoms (local and systemic) within one week after study drug administration;

• Frequency, duration, and severity of active treatment-emergent adverse events (TEAEs), serious AEs (SAEs), adverse events of special concern (AESIs), and new-onset chronic conditions (NOCIs) throughout the active period (4 weeks post-dose) ;

• Serum VP1-specific (GI.1 and GII.4) IgA on day 1 (baseline), day 8, and day 29 (4 weeks after last dose);

• Breast milk VP1-specific (GI.1 and GII.4) IgA on day 1 (baseline), day 8, and day 29 (4 weeks after last dose).

¹ Shah and Hall, Infect Dis Clin North Am. 2018 Mar;32(1):103-118.

About vixter
Vaxart is a clinical-stage biotechnology company developing a pipeline of oral recombinant vaccines based on its proprietary delivery platform. The Vaxart vaccine is designed to be administered in a pill, allowing it to be stored and transported without refrigeration and eliminating the risk of needle stick injuries. Vaxart believes its proprietary pill-based vaccine delivery platform is suitable for delivering recombinant vaccines, allowing the company to develop oral versions of currently commercially available vaccines and design recombinant vaccines for new indications. Vaxart’s development program currently includes pill vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine against human papillomavirus (HPV), which is Vaxart’s first An immuno-oncology indication. Vaxart has filed extensive domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

A Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve significant risks and uncertainties. Except for statements of historical facts, statements contained in this press release regarding Vaxart’s strategy, prospects, plans and objectives, preclinical and clinical trial results and the timing of such results, commercialization agreements and licenses and management’s beliefs and expectations All statements are forward-looking statements. These forward-looking statements may be identified by words such as “should,” “believe,” “could,” “potential,” “will,” “anticipate,” “anticipate,” “plan” and other words and terminology. Pretty much the same meaning. Examples of such statements include, but are not limited to, statements related to Vaxart’s ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart’s expectations regarding clinical results and trial data, and the receipt and reporting of such clinical results and the timing of trial data; Vaxart’s expectations for the effectiveness of its product candidates. Vaxart may not actually achieve plans, execute intentions or meet the expectations or projections disclosed in forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events may differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements made by Vaxart, including the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, the commencement and/or completion dates of clinical trials, regulatory submissions date, regulatory approval date and/or launch date, and the possibility of adverse new clinical data and further analysis of existing clinical data; the risk that clinical trial data will be subject to different interpretations and evaluations by regulatory authorities; the design and results of clinical studies by regulatory authorities Satisfactory; Decisions made by regulatory agencies affecting labeling, manufacturing processes and safety may affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory agencies; even if Vaxart’s product candidates may also not achieve broad market acceptance without approval from the FDA or non-U.S. regulatory authorities; Vaxart’s collaborators may not achieve development and commercial milestones; Vaxart’s collaborators may not achieve development and commercial milestones due to events within or beyond the control of Vaxart or its collaborators , Vaxart or its partners may experience manufacturing issues and delays; difficulties in production, particularly in scaling up initial production, including production costs and throughput, quality control (including stability and quality assurance testing of product candidates), qualified personnel or Shortages of critical raw materials and difficulties in strictly enforcing federal, state and foreign regulations; Vaxart may be unable to obtain, maintain and enforce necessary patent and other intellectual property protection; Vaxart’s capital resources may be insufficient; Vaxart’s ability to resolve outstanding legal issues ; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government health care proposals and policies; competitive factors; “risks” in Vaxart’s quarterly and annual reports filed with the SEC and other risks described in the Factors section. Vaxart assumes no obligation to update any forward-looking statements except as required by law.

Contact information